Dhanuka Agritech Q4 FY26: Margin gains in a soft quarter, with guidance signaling pressure ahead

Dhanuka Agritech Limited closed Q4 FY2025-26 with higher profits even as the quarter remained seasonally softer for the agrochemical industry. Revenue from operations rose to Rs. 483.34 crore from Rs. 442.02 crore a year ago, a year on year increase of 9.35 percent. Operating performance also improved, with EBITDA rising to Rs. 124.89 crore from Rs. 109.75 crore. The EBITDA margin expanded to 25.84 percent from 24.83 percent. Profit after tax increased to Rs. 97.77 crore from Rs. 75.50 crore, taking the PAT margin to 20.23 percent from 17.08 percent.

The underlying context matters. Management described Q4 as a relatively softer period for the sector, with the Rabi season further affected by unfavorable climatic conditions in some key regions. The operating environment stayed difficult, shaped by erratic weather, uneven crop economics, weak channel liquidity in parts of the market, and global volatility in commodities and supply chain dynamics that became more visible in March due to the war in the Gulf region. Even in this backdrop, Dhanuka delivered an earnings improvement for the quarter, helped by cost discipline and a sharp rise in other income.

A quarter where profit outpaced revenue

The quarter’s revenue growth was steady, but the more notable movement was in profitability. Gross profit grew to Rs. 205.88 crore from Rs. 191.16 crore, though gross margin dipped slightly to 42.60 percent from 43.25 percent. That modest gross margin compression did not prevent margin expansion at the EBITDA level because other expenses fell meaningfully to Rs. 30.61 crore from Rs. 41.20 crore, a year on year decline of 25.70 percent.

At the same time, employee benefit expenses increased to Rs. 50.37 crore from Rs. 40.21 crore, up 25.27 percent. The combined effect suggests that while people costs rose, operating leverage and tighter control over other costs helped protect profitability. Below EBITDA, depreciation was lower year on year in Q4, finance costs were lower, and other income increased sharply to Rs. 20.53 crore from Rs. 11.16 crore, which helped lift profit before tax to Rs. 128.31 crore from Rs. 101.66 crore.

For investors, the quarter reads as a reminder that the company can protect earnings in a volatile demand environment, but that some of the profit uplift came from lines that can swing quarter to quarter, such as other income.

A diversified revenue base across regions and segments

Dhanuka’s Q4 revenue mix showed broad balance across geographies. In Q4 FY26, North contributed 32 percent, South 33 percent, East 12 percent, and West 23 percent. A year ago, the split was North 34 percent, South 34 percent, East 12 percent, and West 20 percent. The most visible shift was a higher share from the West, suggesting improved traction in that region, while North and South remained the largest contributors.

The business also stayed diversified by segment. In Q4 FY26, insecticides formed 41 percent of revenue, fungicides 14 percent, herbicides 31 percent, and others 14 percent. In Q4 FY25, insecticides were 38 percent, fungicides 13 percent, herbicides 32 percent, and others 17 percent. The segment mix points to higher insecticide contribution and a lower share of others, while herbicides remained largely stable.

This balance across regions and segments is not just a portfolio statistic. It reduces dependence on any single crop cycle or geography, which matters when management is explicitly highlighting the role of weather and channel liquidity in shaping demand.

Strategy anchored in distribution reach and R&D focus

The company’s operating model is built around reach and product breadth. Dhanuka highlighted its pan India presence across major states and its ability to reach more than 10 million farmers. The distribution backbone includes 41 warehouses, around 6,500 distributors, and 80,000 retailers. For an agrochemical company, this matters because demand can be highly time sensitive around sowing patterns and weather. A wide network can help push availability deeper into markets, but it also requires careful channel management, especially when management flags weak liquidity in certain regions.

On the product side, Dhanuka has over 300 registrations across herbicides, insecticides, fungicides, and plant growth regulators, and around 90 products across segments. It is also positioning itself around new chemistry and tie ups with global innovators from the US, Japan, and Europe to bring newer technologies to Indian farms.

Execution is also linked to in house capability. The presentation referenced a synthesis plant at Dahej supported by a fully equipped R&D lab with 30 chemists. Over the last couple of years, the company has set up two research and technology centers, one focused on applied chemistry and formulation development, and another focused on process technology innovation for generic and late stage patented products.

The strategic emphasis for the pipeline is on margin accretive 9(3) products and launches across segments, including me too products, over the next two years. For investors, the key question is how quickly these launches scale, because management’s FY2026-27 guidance includes lower double digit growth in revenue but an expected EBITDA margin decline of about 100 basis points. That guidance suggests the company expects either higher costs, a tougher mix, or heavier spending to support growth.

One more indicator that helps frame the product refresh cycle is the innovation turnover index, measured as new molecules as a percentage of total revenue. It stood at 13.93 percent in FY26, slightly lower than 14.93 percent in FY25, but well above FY22 levels. The trend suggests the company has increased the contribution of newer molecules over time, though FY26 indicates some normalization.

Capital returns and alignment signals in a volatile backdrop

Beyond operations, the board announced three decisions that shape the shareholder and employee narrative. First, the board recommended a dividend of 100 percent, or Rs. 2 per equity share of face value Rs. 2, subject to shareholder approval at the 41st AGM on 31 July 2026. The dividend is expected to absorb about Rs. 9.02 crore.

Second, the board approved a buyback of up to 5 lakh equity shares for an aggregate amount not exceeding Rs. 70 crore at a maximum buyback price of Rs. 1,400 per share. In a year where the company faced a mixed demand environment and modest full year revenue decline, the buyback signals confidence in cash generation and balance sheet strength.

Third, the board approved the introduction of an employee stock option plan. Management framed it as a way to strengthen entrepreneurial mindset, enhance long term alignment, and support the next phase of growth and leadership development. For investors, ESOP design and dilution impact usually determine the real outcome, but the intent is clear: retain talent and align incentives as the product pipeline expands.

Full year picture: stable revenue, softer profits, and what that implies

While Q4 improved year on year, FY26 tells a more measured story. Revenue from operations for FY26 was Rs. 2,019.79 crore versus Rs. 2,035.15 crore in FY25, a decline of 0.75 percent. EBITDA was Rs. 403.48 crore compared with Rs. 416.61 crore, down 3.15 percent, and PAT declined to Rs. 287.23 crore from Rs. 296.96 crore, down 3.28 percent.

Margins remained relatively stable at the gross level for the year, with gross margin at 40.27 percent in FY26 versus 40.10 percent in FY25. But EBITDA margin slipped to 19.98 percent from 20.47 percent, and PAT margin to 14.22 percent from 14.59 percent. The annual trend table in the presentation shows that FY25 was a strong profitability year versus earlier years, and FY26 eased from that peak while staying above FY21 to FY24 in margin terms.

That context makes the FY2026-27 guidance more important than it might appear at first glance. Lower double digit revenue growth suggests management expects demand to recover, likely linked to monsoon progression and reservoir conditions. But an expected EBITDA decline of about 100 basis points implies that the recovery may not be clean, either because competition, input costs, channel support, or product mix could weigh on profitability.

Takeaways for investors

Dhanuka’s Q4 FY26 performance shows resilience. Revenue grew close to 10 percent and profit growth was stronger, supported by lower other expenses and higher other income. Mix remained diversified across regions and segments, which helps when weather patterns and channel conditions are uneven.

At the same time, FY26 was slightly softer than FY25 on revenue and profits, and management has already guided for margin pressure in FY2026-27 even as it expects lower double digit growth. That guidance sets a realistic frame: the near term remains linked to monsoon and farm economics, while the medium term rests on execution of product launches, the 9(3) focused pipeline, and the ability to keep the distribution engine efficient.

The dividend recommendation, buyback approval, and ESOP announcement add a capital return and alignment layer to the story. The company is signaling confidence, but the next year will test how well growth and margin priorities can be balanced in a volatile external environment.